PRAX News and Press, Praxis Precision Medicines Inc. From 12/02/21

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today ann...

BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today ann...

BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today ann...

Compass Pathways is the category leader in developing psilocybin to treat depression and other CNS disorders. The company's lead asset, COMP360, has very promising efficacy data, but more data is needed to get clarification on safety concerns. As a result, we recommend monitoring ...

Praxis is developing a potential first-in-class drug candidate, PRAX-114, in major depressive disorder. With clinical catalysts coming up in early 2022 for PRAX-114, there is a window of opportunity to invest in the company. Praxis also has a unique rare-to-common drug discovery p...

Start Time: 08:30 End Time: 09:22 Praxis Precision Medicines, Inc. (PRAX) Q3 2021 Earnings Conference Call November 03, 2021, 08:30 AM ET Company Participants Marcio Souza - President and CEO Bernard Ravina - Chief Medical Officer Tim Kelly - CFO Alex Kane - VP of IR and Corporate Communicati...

Praxis Precision Medicines (NASDAQ:PRAX) has filed for a mixed shelf offering. The amount was not disclosed. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Praxis' most advanced asset is PRAX-114 in phase 2/3 for major depressive disorder. Pr...

The following slide deck was published by Praxis Precision Medicines, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Praxis Precision Medicines, Inc. 2021 Q3 - Results - Earnings Call Presentation

Praxis Precision Medicines (NASDAQ:PRAX): Q3 GAAP EPS of -$1.00 misses by $0.07. As of September 30, 2021, the company had $314.4 million in cash, cash equivalents and marketable securities, compared to $296.6 million in cash and cash equivalents as of December 31, 2020. Press Release For f...

Enrollment on track for 1H22 topline results for PRAX-114 Phase 2/3 monotherapy MDD Aria Study and for PRAX-114 Phase 2 dose-ranging MDD Acapella Study PRAX-114 Phase 2 studies in post-traumatic stress disorder and essential tremor (ET), PRAX-562 Phase 2 study in rare adult ceph...